Eladi kasaya in the management of Asrigdara
Phase 3
- Conditions
- Health Condition 1: N920- Excessive and frequent menstruation with regular cycle
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients who are willing to give written consent for the trial.
2. Patients between the age group of 18 to 45years.
3. Patients with excessive bleeding ( >80ml) for at least 2 consecutive cycles.
Exclusion Criteria
1. Patients with any diagnosed uterine organic pathology like Uterine Fibroid, Adenomyosis, Chronic tubo ovarian mass. Polycystic ovaries
2. Patients with systemic diseases like hypertension, diabetes mellitus, congestive cardiac failure etc.
3. Patients with coagulopathy
4. Liver dysfunction
5. Thyroid dysfunction
6. Patients with malignancy or undiagnosed neoplasm.
7. Patients with history of recent abortion.
8. Patients with active genital tuberculosis.
9. Bleeding from the polyps and erosion.
10. IUCD in utero, pelvic endometriosis.
11. Hb < 8 gm/dl.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction of blood loss calculated by pictorial blood assessment chart <br/ ><br>Timepoint: 0,4weeks, 8weeks, 12weeks, 16weeks
- Secondary Outcome Measures
Name Time Method improvement in hemoglobinTimepoint: 0 and 16 weeks;quality of life assessment using menorrhagia impact quessionnaireTimepoint: 0 and 16 weeks;reduction in pain assessed by visual analog scaleTimepoint: 4weeks, 8weeks, 12 weeks, 16weeks;safety of given medication through occurance of adverse drug reaction <br/ ><br>Timepoint: 4,8,12 week